Article: Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleRecombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region
AuthorsChen, Z1
Zhang, L1
Qin, C1
Ba, L1
Yi, CE1
Zhang, F1
Wei, Q1
He, T1
Yu, W1
Yu, J1
Gao, H1
Tu, X1
Gettie, A1
Farzan, M1
Yuen, KY1
Ho, DD1
Issue Date2005
PublisherAmerican Society for Microbiology. The Journal's web site is located at http://jvi.asm.org/
CitationJournal Of Virology, 2005, v. 79 n. 5, p. 2678-2688 [How to Cite?]
DOI: http://dx.doi.org/10.1128/JVI.79.5.2678-2688.2005
AbstractImmunization with a killed or inactivated viral vaccine provides significant protection in animals against challenge with certain corresponding pathogenic coronaviruses (CoVs). However, the promise of this approach in humans is hampered by serious concerns over the risk of leaking live severe acute respiratory syndrome (SARS) viruses. In this study, we generated a SARS vaccine candidate by using the live-attenuated modified vaccinia virus Ankara (MVA) as a vector. The full-length SARS-CoV envelope Spike (S) glycoprotein gene was introduced into the deletion III region of the MVA genome. The newly generated recombinant MVA, ADS-MVA, is replication incompetent in mammalian cells and highly immunogenic in terms of inducing potent neutralizing antibodies in mice, rabbits, and monkeys. After two intramuscular vaccinations with ADS-MVA alone, the 50% inhibitory concentration in serum was achieved with reciprocal sera dilutions of more than 1,000- to 10,000-fold in these animals. Using fragmented S genes as immunogens, we also mapped a neutralizing epitope in the region of N-terminal 400 to 600 amino acids of the S glycoprotein (S400-600), which overlaps with the angiotensin-converting enzyme 2 (ACE2) receptor-binding region (RBR; S318-510). Moreover, using a recombinant soluble RBR-Fc protein, we were able to absorb and remove the majority of the neutralizing antibodies despite observing that the full S protein tends to induce a broader spectrum of neutralizing activities in comparison with fragmented S proteins. Our data suggest that a major mechanism for neutralizing SARS-CoV likely occurs through blocking the interaction between virus and the cellular receptor ACE2. In addition, ADS-MVA induced potent immune responses which very likely protected Chinese rhesus monkeys from pathogenic SARS-CoV challenge.
ISSN0022-538X
2011 Impact Factor: 5.402
2011 SCImago Journal Rankings: 0.745
DOIhttp://dx.doi.org/10.1128/JVI.79.5.2678-2688.2005
PubMed Central IDPMC548443
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorChen, Z
dc.contributor.authorZhang, L
dc.contributor.authorQin, C
dc.contributor.authorBa, L
dc.contributor.authorYi, CE
dc.contributor.authorZhang, F
dc.contributor.authorWei, Q
dc.contributor.authorHe, T
dc.contributor.authorYu, W
dc.contributor.authorYu, J
dc.contributor.authorGao, H
dc.contributor.authorTu, X
dc.contributor.authorGettie, A
dc.contributor.authorFarzan, M
dc.contributor.authorYuen, KY
dc.contributor.authorHo, DD
dc.date.accessioned2008-06-12T06:35:44Z
dc.date.available2008-06-12T06:35:44Z
dc.date.issued2005
dc.description.abstractImmunization with a killed or inactivated viral vaccine provides significant protection in animals against challenge with certain corresponding pathogenic coronaviruses (CoVs). However, the promise of this approach in humans is hampered by serious concerns over the risk of leaking live severe acute respiratory syndrome (SARS) viruses. In this study, we generated a SARS vaccine candidate by using the live-attenuated modified vaccinia virus Ankara (MVA) as a vector. The full-length SARS-CoV envelope Spike (S) glycoprotein gene was introduced into the deletion III region of the MVA genome. The newly generated recombinant MVA, ADS-MVA, is replication incompetent in mammalian cells and highly immunogenic in terms of inducing potent neutralizing antibodies in mice, rabbits, and monkeys. After two intramuscular vaccinations with ADS-MVA alone, the 50% inhibitory concentration in serum was achieved with reciprocal sera dilutions of more than 1,000- to 10,000-fold in these animals. Using fragmented S genes as immunogens, we also mapped a neutralizing epitope in the region of N-terminal 400 to 600 amino acids of the S glycoprotein (S400-600), which overlaps with the angiotensin-converting enzyme 2 (ACE2) receptor-binding region (RBR; S318-510). Moreover, using a recombinant soluble RBR-Fc protein, we were able to absorb and remove the majority of the neutralizing antibodies despite observing that the full S protein tends to induce a broader spectrum of neutralizing activities in comparison with fragmented S proteins. Our data suggest that a major mechanism for neutralizing SARS-CoV likely occurs through blocking the interaction between virus and the cellular receptor ACE2. In addition, ADS-MVA induced potent immune responses which very likely protected Chinese rhesus monkeys from pathogenic SARS-CoV challenge.
dc.description.naturepublished_or_final_version
dc.format.extent386 bytes
dc.format.mimetypetext/html
dc.identifier.citationJournal Of Virology, 2005, v. 79 n. 5, p. 2678-2688 [How to Cite?]
DOI: http://dx.doi.org/10.1128/JVI.79.5.2678-2688.2005
dc.identifier.doihttp://dx.doi.org/10.1128/JVI.79.5.2678-2688.2005
dc.identifier.epage2688
dc.identifier.hkuros109678
dc.identifier.isiWOS:000227098400004
dc.identifier.issn0022-538X
2011 Impact Factor: 5.402
2011 SCImago Journal Rankings: 0.745
dc.identifier.issue5
dc.identifier.openurl
dc.identifier.pmcidPMC548443
dc.identifier.pmid15708987
dc.identifier.scopuseid_2-s2.0-13944272585
dc.identifier.spage2678
dc.identifier.urihttp://hdl.handle.net/10722/49158
dc.identifier.volume79
dc.languageeng
dc.publisherAmerican Society for Microbiology. The Journal's web site is located at http://jvi.asm.org/
dc.publisher.placeUnited States
dc.relation.ispartofJournal of Virology
dc.relation.referencesReferences in Scopus
dc.rightsJournal of Virology. Copyright © American Society for Microbiology.
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
dc.rightsCopyright © American Society for Microbiology, Journal of Virology, 2005, v. 79 n. 5, p. 2678-2688
dc.subject.meshAntibodies, Viral - biosynthesis
dc.subject.meshMembrane Glycoproteins - chemistry - genetics - immunology
dc.subject.meshSARS Virus - genetics - immunology
dc.subject.meshVaccinia virus - genetics
dc.subject.meshViral Envelope Proteins - chemistry - genetics - immunology
dc.titleRecombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region
dc.typeArticle
Author Affiliations
  1. Rockefeller University